Company intelligence / Profile preview

Maiwei Biotech

Shenzhen, Guangdong, Chinamaiweibio.com ↗

Ownership: Private
Employees: ~90
Development stage: Other

Overview

Maiwei Biotech has a robust pipeline with 16 varieties at different stages—12 innovative drugs and 4 biosimilars. Three products have been launched commercially. One NDA has been accepted. Three additional programs are in critical registration clinical trial stages. The company operates GMP-compliant manufacturing facilities that meet China NMPA, US FDA, and EU EMA standards. It is involved in national-level science/technology projects and maintains a strong innovation focus with global reach.

Therapeutic areas: OncologyImmunologyHematologyRheumatologyOphthalmologyInfectious Diseases
Modalities: Monoclonal antibodyRecombinant proteinBiosimilar
Industry: Biotech

Partnerships

Risen Pharma – licensing agreement to co-develop drugs in bone health field

Beyond the preview

Go deeper on Maiwei Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Maiwei Biotech.